Non-Hodgkin Lymphoma

  • Catherine Patte
  • Archie Bleyer
  • Mitchell S. Cairo
Part of the Pediatric Oncology book series (PEDIATRICO)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bleyer WA, O’Leary M, Barr R, Ries LAG (eds) (2006) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD; also available at Scholar
  2. 2.
    Birch JM, Alston RD, Quinn M, Kelsey AM (2003) Incidence of malignant disease by morphological type, in young persons aged 12–24 years in England, 1979–1997. Eur J Cancer 39:2622–2631PubMedGoogle Scholar
  3. 3.
    Perkins SL, Raphael M, McCarthy K, et al (2003) Pediatric mature B-cell lymphoma: distribution of lymphoma subtype varies between national groups. Results from the FAB/LMB96 International Cooperative Group Study. Blood 102:1428 (abstract)Google Scholar
  4. 4.
    Jaffe E, Harris N, Stein H, Vardiman J (eds) (2000) World Health Organization Classifiction of Tumors. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Washington DCGoogle Scholar
  5. 5.
    Harris N, Jaffe E, Stein H, et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392PubMedGoogle Scholar
  6. 6.
    Shipp MA, Ross KN, Tamayo P, et al (2002) Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. Nat Med 8:68–74PubMedGoogle Scholar
  7. 7.
    Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 7:332–339PubMedGoogle Scholar
  8. 8.
    Patte C, Sakiroglu C, Ansoborlo S, et al (2002) Urateoxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d’Oncologie Pédiatrique LMB89 protocol. Ann Oncol 13:789–795PubMedGoogle Scholar
  9. 9.
    Pui CH, Mahmoud HH, Wiley JM, et al (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697–704PubMedGoogle Scholar
  10. 10.
    Goldman SC, Holcenberg JS, Finklestein JZ, et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998–3003PubMedGoogle Scholar
  11. 11.
    Coiffier B, Mounier N, Bologna S, et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21:4402–4406PubMedGoogle Scholar
  12. 12.
    Patte C, Philip T, Rodary C, et al (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4:1219–1226PubMedGoogle Scholar
  13. 13.
    Patte C, Philip T, Rodary C, et al (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132PubMedGoogle Scholar
  14. 14.
    Patte C, Auperin A, Michon J, et al (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379PubMedGoogle Scholar
  15. 15.
    Reiter A, Schrappe M, Parwaresch R, et al (1995) Non-Hodgkin lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage — a report of the Berlin-Frankfurt-Munster group. J Clin Oncol 13:359–372PubMedGoogle Scholar
  16. 16.
    Reiter A, Schrappe M, Tiemann M, et al (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHLBFM 90. Blood 94:3294–3306PubMedGoogle Scholar
  17. 17.
    Magrath I, Adde M, Shad A, et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934PubMedGoogle Scholar
  18. 18.
    Atra A, Gerrard M, Hobson R, et al (1998) Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin lymphoma (B-NHL) — results of the UKCCSG 9003 protocol. Br J Cancer 77:2281–2285PubMedGoogle Scholar
  19. 19.
    Atra A, Imeson JD, Hobson R, et al (2000) Improved outcome in children with advanced stage B-cell non-Hodgkin lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 82:1396–1402PubMedGoogle Scholar
  20. 20.
    Spreafico F, Massimino M, Luksch R, et al (2002) Intensive, very short-term chemotherapy for advanced Burkitt lymphoma in children. J Clin Oncol 20:2783–2788PubMedGoogle Scholar
  21. 21.
    Murphy SB, Hustu HO, Rivera G, Berard CW (1983) End results of treating children with localized non-Hodgkin lymphomas with a combined modality approach of lessened intensity. J Clin Oncol 1:326–330PubMedGoogle Scholar
  22. 22.
    Link MP, Shuster JJ, Donaldson SS, et al (1997) Treatment of children and young adults with early-stage non-Hodgkin lymphoma. N Engl J Med 337:1259–1266PubMedGoogle Scholar
  23. 23.
    Meadows AT, Sposto R, Jenkin RD, et al (1989) Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 7:92–99PubMedGoogle Scholar
  24. 24.
    Gerrard M, Cairo MS, Patte C, et al (2003) Results of the FAB international study in children and adolescents (C+A) with localised B-NHL (large cell [LCL], Burkitt [BL] and Burkitt-like [BLL]). Proc ASCO 22:795 (abstract)Google Scholar
  25. 25.
    Reiter A, Schrappe M, Zimmermann M, et al (2003) Randomized trial of high dose methotrexate I.V. infusion over 24 hours versus 4 hours as part of combination chemotherapy for childhood and adolescent B-cell neoplasms. A report of the BFM Group. J Pediatr Hematol Oncol 25:S2 (abstract)Google Scholar
  26. 26.
    Patte C, Gerrard M, Auperin A, et al (2003) Early treatment intensity has a major prognostic impact in the “intermediate risk” childhood and adolescent B-cell lymphoma: results of the international FAB LMB 96 trial. Blood 102:491 (abstract)Google Scholar
  27. 27.
    Pusill-Wachtsmuth B, Zimmermann M, Seidemann K, et al (2003) Non-Hodgkin-lymphoma of adolescence: treatment results in the pediatric multicenter studies NHL-BFM. J Pediatr Hematol Oncol 25:S2 (abstract)Google Scholar
  28. 28.
    Todeschini G, Tecchio C, Degani D, et al (1997) Eightyone percent event-free survival in advanced Burkitt lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 8:77–81PubMedGoogle Scholar
  29. 29.
    Corbacioglu S, Eber S, Gungor T, et al (2003) Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol Oncol 25:327–329PubMedGoogle Scholar
  30. 30.
    de Vries MJ, Veerman AJ, Zwaan CM (2004) Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin lymphoma. Br J Haematol 125:414–415PubMedGoogle Scholar
  31. 31.
    Cairo MS, Sposto R, Hoover-Regan M, et al (2003) Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol 72:53–63PubMedGoogle Scholar
  32. 32.
    Laver JH, Mahmoud H, Pick TE, et al (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105–109PubMedGoogle Scholar
  33. 33.
    Patte C, Auperin A, Bergeron C, et al (2002) Large Bcell lymphoma (LBCL) in children: similarities and differences with Burkitt (BL) in children and LBCL in adults. Experience of the SFOP LMB89 study. Ann Oncol 13:110 (abstract #379)Google Scholar
  34. 34.
    Laver JH, Weinstein HJ, Hutchison RE, et al (2001) Lineage-specific differences in outcome for advanced stage large cell lymphoma in children and adolescents: results of a randomized phase III Pediatric Oncology Group Trial. Blood 98:345a (abstract)Google Scholar
  35. 35.
    Alizadeh AA, Eisen MB, Davis RE, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedGoogle Scholar
  36. 36.
    Coiffier B, Lepage E, Briere J, et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedGoogle Scholar
  37. 37.
    Pfreundschuh MG, Trumper L, Ma D, et al (2004) Randomized intergroup trial of first line treatment for patients <= 60 years with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab — early stopping after the first interim analysis. Proc ASCO 23:6500 (abstract)Google Scholar
  38. 38.
    Savage KJ, Monti S, Kutok JL, et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871–3879PubMedGoogle Scholar
  39. 39.
    Patte C, Gerrard M, Auperin A, et al (2003) Results of the randomised international trial FAB LMB 96 for the “intermediate risk” childhood and adolescent B-cell lymphoma: reduced therapy is efficacious. Proc ASCO 22:796 (abstract)Google Scholar
  40. 40.
    Seidemann K, Tiemann M, Lauterbach I, et al (2003) Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 21:1782–1789PubMedGoogle Scholar
  41. 41.
    Lones MA, Perkins SL, Sposto R, et al (2000) Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J Clin Oncol 18:3845–3853PubMedGoogle Scholar
  42. 42.
    Stein H, Mason DY, Gerdes J, et al (1985) The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858PubMedGoogle Scholar
  43. 43.
    Rimokh R, Magaud JP, Berger F, et al (1989) A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol 71:31–36PubMedGoogle Scholar
  44. 44.
    Morris SW, Kirstein MN, Valentine MB, et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin lymphoma. Science 263:1281–1284PubMedGoogle Scholar
  45. 45.
    Chott A, Kaserer K, Augustin I, et al (1990) Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol 14:439–448PubMedGoogle Scholar
  46. 46.
    Delsol G, Al Saati T, Gatter KC, et al (1988) Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130:59–70PubMedGoogle Scholar
  47. 47.
    Nakamura S, Takagi N, Kojima M, et al (1991) Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese. Cancer 68:118–129PubMedGoogle Scholar
  48. 48.
    Greer JP, Kinney MC, Collins RD, et al (1991) Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539–547PubMedGoogle Scholar
  49. 49.
    Shiota M, Nakamura S, Ichinohasama R, et al (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86:1954–1960PubMedGoogle Scholar
  50. 50.
    Gascoyne RD, Aoun P, Wu D, et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921PubMedGoogle Scholar
  51. 51.
    Falini B, Pileri S, Pizzolo G, et al (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1–14PubMedGoogle Scholar
  52. 52.
    Stein H, Foss HD, Durkop H, et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681–3695PubMedGoogle Scholar
  53. 53.
    Fraga M, Brousset P, Schlaifer D, et al (1995) Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103:82–89PubMedGoogle Scholar
  54. 54.
    Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al (1998) ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91:2076–2084PubMedGoogle Scholar
  55. 55.
    Jaffe ES (2001) Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219–228PubMedGoogle Scholar
  56. 56.
    Willemze R, Beljaards RC (1993) Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973–980PubMedGoogle Scholar
  57. 57.
    Vergier B, Beylot-Barry M, Pulford K, et al (1998) Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 22:1192–1202PubMedGoogle Scholar
  58. 58.
    DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME (1996) The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 87:3437–3441PubMedGoogle Scholar
  59. 59.
    Drexler HG, Gignac SM, von Wasielewski R, et al (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14:1533–1559PubMedGoogle Scholar
  60. 60.
    Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:5623–5637PubMedGoogle Scholar
  61. 61.
    Gascoyne RD, Adomat SA, Krajewski S, et al (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin lymphoma. Blood 90:244–251PubMedGoogle Scholar
  62. 62.
    Murphy SB (1994) Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol 5:31–33PubMedGoogle Scholar
  63. 63.
    Seidemann K, Tiemann M, Schrappe M, et al (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97:3699–3706PubMedGoogle Scholar
  64. 64.
    Sandlund JT, Pui CH, Santana VM, et al (1994) Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin lymphoma. J Clin Oncol 12:895–898PubMedGoogle Scholar
  65. 65.
    Williams DM, Hobson R, Imeson J, et al (2002) Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 117:812–820PubMedGoogle Scholar
  66. 66.
    Massimino M, Spreafico F, Luksch R, Giardini R (2001) Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol 37:97–102PubMedGoogle Scholar
  67. 67.
    Brugieres L, Deley MC, Pacquement H, et al (1998) CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591–3598PubMedGoogle Scholar
  68. 68.
    Suzuki R, Kagami Y, Takeuchi K, et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000PubMedGoogle Scholar
  69. 69.
    Sandlund JT, Pui CH, Roberts WM, et al (1994) Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 84:2467–2471PubMedGoogle Scholar
  70. 70.
    Cairo MS, Krailo MD, Morse M, et al (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate („Orange“) in children with advanced non-lymphoblastic non-Hodgkin lymphoma. A Children’s Cancer Group report. Leukemia 16:594–60PubMedGoogle Scholar
  71. 71.
    Reiter A, Schrappe M, Tiemann M, et al (1994) Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12:899–908PubMedGoogle Scholar
  72. 72.
    Mora J, Filippa DA, Thaler HT, et al (2000) Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer 88:186–197PubMedGoogle Scholar
  73. 73.
    Abromowitch M, Sposto R, Perkins SL, et al (2002) Preliminary results of CCG-5941: a pilot study in children and adolescents with anaplastic large cell lymphoma. Ann Oncol 13:erratumGoogle Scholar
  74. 74.
    Fanin R, Silvestri F, Geromin A, et al (1996) Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/− radiotherapy) and autologous bone marrow transplantation. Blood 87:1243–1248PubMedGoogle Scholar
  75. 75.
    Sternberg C (1916) Leukosarkomatose and myelobastenleukaamie. Beitr Pathol 61:75Google Scholar
  76. 76.
    Barcos MGP, Lukes RJ (1975) Malignant lymphoma of the convoluted lymphocytes: a new entity of possible T-cell type. In: Sinks L, Godden J (eds) Conflicts in Childhood Cancer: An Evaluation of Current Management. Liss, New York, p 147Google Scholar
  77. 77.
    Amylon MD, Shuster J, Pullen J, et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335–342PubMedGoogle Scholar
  78. 78.
    Tubergen DG, Krailo MD, Meadows AT, et al (1995) Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin lymphoma: a Childrens Cancer Group study. J Clin Oncol 13:1368–1376PubMedGoogle Scholar
  79. 79.
    Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98:1283–1291PubMedGoogle Scholar
  80. 80.
    Reiter A, Schrappe M, Ludwig WD, et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416–421PubMedGoogle Scholar
  81. 81.
    Thomas DA, Kantarjian HM (2001) Lymphoblastic lymphoma. Hematol Oncol Clin North Am 15:51–95PubMedGoogle Scholar
  82. 82.
    Colgan JP, Andersen J, Habermann TM, et al (1994) Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin lymphoma. Leuk Lymphoma 15:291–296PubMedGoogle Scholar
  83. 83.
    Hoelzer D, Gokbuget N, Digel W, et al (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379–4385PubMedGoogle Scholar
  84. 84.
    Cairo MS, Raetz E, Perkins SL (2003) Non-Hodgkin lymphoma in children. In: Kufe DW, Pollock RE, Weichselbaum RR, et al (eds) Cancer Medicine (6th edition). Decker, London, pp 2337–2348Google Scholar
  85. 85.
    Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin lymphoma in childhood. N Engl J Med 334:1238–1248PubMedGoogle Scholar
  86. 86.
    Perkins SL (2000) Work-up and diagnosis of pediatric non-Hodgkin lymphomas. Pediatr Dev Pathol 3:374–390PubMedGoogle Scholar
  87. 87.
    Pilozzi E, Muller-Hermelink HK, Falini B, et al (1999) Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267–270PubMedGoogle Scholar
  88. 88.
    Hojo H, Sasaki Y, Nakamura N, Abe M (2001) Absence of somatic hypermutation of immunoglobulin heavy chain variable region genes in precursor B-lymphoblastic lymphoma: a study of four cases in childhood and adolescence. Am J Clin Pathol 116:673–682PubMedGoogle Scholar
  89. 89.
    Link MP, Donaldson SS, Berard CW, et al (1990) Results of treatment of childhood localized non-Hodgkin lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 322:1169–1174PubMedGoogle Scholar
  90. 90.
    Anderson J, Jenkin R, Wilson J, et al (1993) Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 11:1024–1032PubMedGoogle Scholar
  91. 91.
    Wollner N, Burchenal JH, Lieberman PH, et al (1976) Non-Hodgkin lymphoma in children. A comparative study of two modalities of therapy. Cancer 37:123–134PubMedGoogle Scholar
  92. 92.
    Anderson J, Wilson J, Jenkin D, et al (1983) Childhood non-Hodgkin lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308:559–565PubMedGoogle Scholar
  93. 93.
    Asselin B, Shuster JJ, Amylon M, et al (2001) Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 20:1464 (abstract)Google Scholar
  94. 94.
    Millot F, Suciu S, Philippe N, et al (2001) Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increasedrisk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 19:1935–1942PubMedGoogle Scholar
  95. 95.
    Weinstein HJ, Cassady JR, Levey R (1983) Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1:537–541PubMedGoogle Scholar
  96. 96.
    Hvizdala EV, Berard C, Callihan T, et al (1988) Lymphoblastic lymphoma in children — a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. J Clin Oncol 6:26–33PubMedGoogle Scholar
  97. 97.
    Eden OB, Hann I, Imeson J, et al (1992) Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children’s Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 82:310–316PubMedGoogle Scholar
  98. 98.
    Abromowitch M, Sposto R, Prkins S, et al (2000) Outcome of Children’s Cancer Group (CCG) 5941: A pilot study for the treatment of newly diagnosed pediatric patients with disseminated lymphoblastic lymphoma. Proc Am Soc Clin Oncol 19:2295 (abstract)Google Scholar
  99. 99.
    Coleman CN, Picozzi VJ Jr, Cox RS, et al (1986) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637PubMedGoogle Scholar
  100. 100.
    Morel P, Lepage E, Brice P, et al (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078–1085PubMedGoogle Scholar
  101. 101.
    Zinzani PL, Bendandi M, Visani G, et al (1996) Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 23:577–582PubMedGoogle Scholar
  102. 102.
    Bouabdallah R, Xerri L, Bardou VJ, et al (1998) Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: pa report on 62 patients from a single center. Ann Oncol 9:619–625PubMedGoogle Scholar
  103. 103.
    Sweetenham JW, Santini G, Qian W, et al (2001) Highdose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927–2936PubMedGoogle Scholar
  104. 104.
    Levine JE, Harris RE, Loberiza FR, Jr., et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482PubMedGoogle Scholar
  105. 105.
    Falini B, Pileri S, Zinzani PL, et al (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93:2697–2706PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Catherine Patte
    • 1
  • Archie Bleyer
    • 2
  • Mitchell S. Cairo
    • 3
  1. 1.Department of PediatricsInstitut Gustave RoussyVillejuifFrance
  2. 2.St. Charles Medical CenterUSA
  3. 3.Department of Pediatrics Children’s Hospital of NewYork-PresbyterianColumbia UniversityNew YorkUSA

Personalised recommendations